We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Alzheimer's Disease Linked to Common Bacterium

By Biotechdaily staff writers
Posted on 29 Apr 2004
Researchers have found a link between Chlamydia pneumoniae, a common airborne bacterium, and Alzheimer's disease (AD). More...
Their findings were published in the April 2004 issue of Neurobiology of Aging.

The researchers demonstrated that bacteria sprayed into the noses of mice not predisposed to amyloid plaques could cause progressive deposition of plaques, creating a partial model of AD. This finding builds on previous research that found Chlamydia pneumoniae in 90% of brains taken from patients with Alzheimer's disease.

"We believe this could be a trigger mechanism for the pathology in Alzheimer's disease,” said lead researchers Denah Appelt, Ph.D., and Brian Balin, Ph.D., of the Center for the Study of Chronic Diseases of Aging at the Philadelphia College of Osteopathic Medicine (PA, USA). "We also believe that our isolation of Chlamydia pneumoniae from the human Alzheimer's diseased brain and induction of pathology in normal mice is proof of principle that this can be a causative mechanism turning on pathology.”

The researchers want to arrange clinical trials in patients with late-onset AD to investigate the effect of typical antibiotics used for treating C pneumoniae infections. However, they note there is controversy whether any existing antibiotics for C pneumoniae can truly clear the organism from the human body. "But in reality we are not sure whether the antibiotic approach will be sufficient to actually eradicate the infection. Right now, we are thinking that combining antibiotics and anti-inflammatory drugs might be instrumental in treating AD, but obviously we do not have a final answer on that.”

Although AD was thought to be a hereditary disease, research has shown that only 2-5% of cases have a tie to genetic mutations. Of all the people who reach the age of 85, about 50% will develop AD.




Related Links:
Philadelphia College of Osteopathic Med.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.